CAS 1009298-59-2
:AZD-2014
Description:
AZD-2014, also known as a selective inhibitor of the mTOR (mechanistic target of rapamycin) pathway, is a compound that has garnered attention in the field of cancer research. It is classified as a small molecule and is primarily investigated for its potential therapeutic applications in various malignancies, particularly those with dysregulated mTOR signaling. The substance exhibits characteristics typical of mTOR inhibitors, including the ability to impede cell proliferation and induce apoptosis in cancer cells. AZD-2014 has shown promise in preclinical studies, demonstrating efficacy in inhibiting tumor growth and enhancing the effects of other anticancer agents. Its mechanism of action involves the disruption of the mTOR signaling cascade, which plays a crucial role in cell growth, metabolism, and survival. Additionally, AZD-2014 is characterized by its pharmacokinetic properties, which influence its absorption, distribution, metabolism, and excretion in biological systems. Ongoing research aims to further elucidate its therapeutic potential and optimize its use in clinical settings.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-
CAS:Formula:C25H30N6O3Purity:95%Color and Shape:SolidMolecular weight:462.5441Vistusertib
CAS:Vistusertib (AZD2014) is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.Formula:C25H30N6O3Purity:97.08% - 99.06%Color and Shape:SolidMolecular weight:462.54AZD2014
CAS:Controlled Product<p>Applications AZD2014 is a dual mTORC1 and mTORC2 inhibitor. Studies show that AZD2014 induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines.<br>References Guichard, S.M. et al.: Cancer Res., 71, 917 (2012);<br></p>Formula:C25H30N6O3Color and Shape:NeatMolecular weight:462.54Vistusertib
CAS:<p>Vistusertib is a potent and selective inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) that inhibits the activation of Akt, a downstream protein kinase. mTORC1 is an important regulator of cell growth, survival, proliferation, and metabolism. Vistusertib has been shown to be effective in the treatment of various cancers including solid tumours and platinum-resistant ovarian cancer. It has also been shown to have potential as a biomarker for autoimmune diseases because it inhibits autophagy.</p>Formula:C25H30N6O3Purity:Min. 95%Molecular weight:462.54 g/mol
![Benzamide, 3-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-N-methyl-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA000382.jpg&w=3840&q=75)
